Investment Rating - The report maintains a "Recommended" rating for the company, with a target price of 5.5 yuan, compared to the current price of 4.79 yuan [3][7]. Core Insights - The company reported a revenue of 2.995 billion yuan for the first three quarters of 2025, a year-on-year decrease of 16.94%. The net profit attributable to the parent company was a loss of 294 million yuan, with a year-on-year increase in losses of 38.45% [2][7]. - The decline in revenue is attributed to two main factors: adjustments in medical insurance payment policies leading to a decrease in inpatient service volume and the ongoing reform of the DRG payment method, which has reduced the average cost per inpatient [7]. - Despite the short-term pressure on revenue, the company has seen a steady increase in outpatient and emergency services, with a total of 1.9751 million visits, a year-on-year increase of 4.03% [7]. - The company is focusing on strategic growth areas, including high-barrier projects like the proton therapy center, consumer healthcare, and data assetization, which are expected to enhance long-term competitiveness [7]. Financial Summary - For 2025, the company is projected to have total revenue of 4.055 billion yuan, a decrease of 15.8% year-on-year, with a net profit attributable to the parent company expected to be a loss of 343 million yuan [2][8]. - The company’s financial metrics indicate a projected net profit growth rate of 74.5% in 2026 and 214.8% in 2027, suggesting a potential recovery in profitability [8]. - The company’s total assets are estimated to be 10.422 billion yuan in 2025, with a debt-to-equity ratio of 164.2% [8].

Core Viewpoint - On November 18, a total of four listed companies will have their restricted shares unlocked, with a total market value of approximately 4.759 billion yuan [1] Group 1: Company Specifics - International Medical (Stock Code: 000516) will unlock 2.2409 million shares under equity incentive restrictions [1] - Darui Electronics (Stock Code: 300976) will unlock 0.1395 million shares under equity incentive restrictions [1] - Yunzhongma (Stock Code: 603130) will unlock 86.4508 million shares that were restricted prior to issuance [1] - Meai Technology (Stock Code: 688376) will unlock 83.4144 million shares [1]

Core Viewpoint - International Medical emphasizes its commitment to balancing long-term development with shareholder returns, aiming to provide stable and sustainable dividends while leveraging capital market financing to strengthen its core business and enhance competitiveness [2] Summary by Relevant Sections - **Shareholder Returns** - The company is dedicated to offering stable and sustainable dividends to shareholders when conditions permit [2] - **Capital Market Utilization** - The company plans to utilize refinancing through capital markets to solidify its main business and improve core competitiveness [2] - **Profit Distribution and Financing** - Historical profit distribution and financing details are publicly available and should be referenced from relevant disclosures [2]

Core Viewpoint - The company emphasizes its commitment to investor returns, highlighting a strong operational performance since its listing, with a total of 16 cash dividends distributed [1] Group 1: Company Performance - Since 2019, the company has fully transformed to focus on its core medical services business, aligning closely with its development strategy [1] - The company has effectively managed its operations to promote high-quality development and continuously enhance its value [1] Group 2: Market Factors - The stock price is influenced by a combination of macroeconomic conditions, industry cycles, and market sentiment [1] - The company encourages a rational and comprehensive understanding of the capital market for prudent investment decisions [1]

Core Insights - The high-pressure oxygen chamber concept has seen a decline of 0.21%, ranking among the top declines in concept sectors as of the market close on November 13 [1] - Within the sector, companies like Innovation Medical and International Medicine experienced significant declines, while six stocks saw price increases, with Dahu Co., Aoyang Health, and Samsung Medical leading the gains [1] Market Performance - The top-performing concept sectors today include: - Fluorochemical concept: +4.50% - Organic silicon concept: +4.47% - Sodium-ion battery: +4.47% - Lead metal: +4.27% - Phosphorus chemical: +4.25% [2] - The high-pressure oxygen chamber sector experienced a net outflow of 149 million yuan, with eight stocks seeing net outflows [2] Fund Flow Analysis - The stocks with the highest net outflows in the high-pressure oxygen chamber sector include: - Samsung Medical: -60.80 million yuan - Innovation Medical: -57.39 million yuan - International Medicine: -12.53 million yuan [2] - Conversely, the stocks with the highest net inflows include: - Yingkang Life: +10.12 million yuan - Hangyang Co.: +9.74 million yuan [2] Stock Performance - Key stock performances in the high-pressure oxygen chamber sector: - Samsung Medical: +0.37%, turnover rate: 2.18% - Innovation Medical: -2.00%, turnover rate: 13.41% - International Medicine: -0.80%, turnover rate: 1.13% [2]

Core Viewpoint - International Medical (000516) has shown a slight increase in stock price, but the financial performance indicates significant challenges, with declining revenues and profits [1][3]. Financial Performance - As of November 12, 2025, the stock closed at 5.01 CNY, up 1.83% with a trading volume of 464,800 shares and a total transaction value of 231 million CNY [1]. - For the first three quarters of 2025, the company reported a main business revenue of 2.995 billion CNY, a year-on-year decrease of 16.94%, and a net profit attributable to shareholders of -294 million CNY, down 38.45% [3]. - The third quarter alone saw a revenue of 961 million CNY, a decline of 18.95%, and a net profit of -129 million CNY, a staggering drop of 234.24% [3]. Market Position and Ratios - The total market capitalization of International Medical is 11.217 billion CNY, ranking 12th in the medical services industry, which has an average market cap of 19.516 billion CNY [3]. - Key financial ratios include a price-to-earnings ratio of -28.65 and a price-to-book ratio of 3.36, with a gross margin of 6.59%, significantly lower than the industry average of 35.56% [3]. Investment Ratings - In the last 90 days, two institutions have provided ratings for the stock, with one buy rating and one hold rating [4].

Core Viewpoint - International Medical (000516) is progressing with the construction of its proton therapy center, which will utilize the latest Varian ProBeam 360-degree proton therapy system, recognized as one of the most advanced systems globally [1] Group 1: Project Details - The proton therapy center will employ the integrated intensity-modulated proton therapy (IMPT) technology [1] - The system features a superconducting cyclotron, a 360-degree rotating gantry, and high-speed pencil beam scanning technology, positioning it as a leader in the industry [1] - Construction is ongoing as planned, with operations expected to commence upon obtaining the necessary administrative approvals [1]

Core Insights - The company is enhancing operational efficiency while optimizing the quality of medical services through clinical pathway management, reducing drug consumption ratio, and optimizing cost structure [1] Financial Performance - As of Q3 2025, the company's management expense ratio is 10.99%, a year-on-year decrease of 0.54 percentage points and a quarter-on-quarter decrease of 2.13 percentage points [1] - The financial expense ratio stands at 3.43%, with a year-on-year decrease of 0.07 percentage points and a quarter-on-quarter decrease of 0.25 percentage points, indicating initial success in cost control [1]

Core Viewpoint - The company provided insights into the operational budget of its proton therapy center, highlighting the complexity and high costs associated with such medical facilities [1] Group 1: Operational Budget Components - The operational costs of the proton therapy system include fixed asset depreciation and amortization, equipment maintenance and operational costs, daily operational expenses, and labor costs [1] - The proton therapy project is characterized by high technical barriers, large investment scale, and long return periods [1] Group 2: Break-even Point and Demand - The break-even point for the proton therapy center is influenced by various dynamic factors [1] - The Xi'an International Medical Center's proton therapy center is the first of its kind in Northwest China and will officially commence operations after obtaining the necessary administrative approvals [1]

Group 1 - The stock price of International Medical (000516) closed at 4.77 yuan, down 0.63% from last week's 4.8 yuan, with a market cap of 10.68 billion yuan [1] - The stock reached a one-year low of 4.73 yuan on November 6, with a highest price of 4.84 yuan on November 3 [1] - The company ranks 16th out of 50 in the medical services sector by market capitalization and 1790th out of 5166 in the A-share market [1] Group 2 - The controlling shareholder, Shaanxi Century New Yuan Commercial Management Co., Ltd., released 34,064,211 shares from pledge, accounting for 1.52% of the total share capital [2][3] - After the release, the total pledged shares by Century New Yuan amount to 448,950,000, which is 72.87% of its holdings and 20.05% of the total share capital [2] - Century New Yuan and its concerted parties hold a total of 718,645,251 shares, representing 32.10% of the total share capital, with pledged shares accounting for 65.99% of their holdings [2][3]